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Recent studies have investigated the use of retinoic acid (RA) molecule in 
combined chemotherapies to cancer cells as an attempt to increase treatment 
efficiency and circumvent cell resistance. Positive results were obtained in clinical 
trials from lung cancer patients treated with RA and cisplatin. Meanwhile, the 
signalling process that results from the interaction of both molecules remains 
unclear. One of the pathways that RA is able to modulate is the activity of NRF2 
transcription factor, which is highly associated with tumour progression and 
resistance. Therefore, the aim of this work was to investigate molecular 
mechanism of RA and cisplatin co-treatment in A549 cells, focusing in NRF2 
pathway. To this end, we investigated NRF2 and NRF2-target genes expression, 
cellular redox status, cisplatin-induced apoptosis, autophagy and DNA repair 
through homologous recombination. RA demonstrated to have an inhibitory effect 
over NRF2 activation, which regulates the expression of thiol antioxidants 
enzymes. Moreover, RA increased reactive species production associated with 
increased oxidation of thiol groups within the cells. The expression of proteins 
associated with DNA repair through homologous recombination was also 
suppressed by RA pre-treatment. All combined, these effects appear to create a 
more sensitive cellular environment to cisplatin treatment, increasing apoptosis 
frequency. Interestingly, autophagy was also increased by combination therapy, 
suggesting a resistance mechanism by A549 cells. In conclusion, these results 
provided new information about molecular mechanisms of RA and cisplatin 
treatment contributing to chemotherapy optimization. 
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